IART
NASDAQIntegra LifeSciences Holdings Corporation
SectorHealth CareIndustryMedical/Dental Instruments
Price$17.14+7.28 (+73.71%)
2026-03-052026-06-08
News · 26 weeks47-56%
2025-12-142026-06-07
Mix3790d
- Insider16(43%)
- SEC Filings8(22%)
- Other7(19%)
- Earnings3(8%)
- Analyst2(5%)
- Leadership1(3%)
Latest news
25 items- INSIDERSEC Form 4 filed by EVP & Chief Commercial Officer Mcbreen Michael J.4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
- INSIDERSEC Form 4 filed by President and CEO Essig Stuart4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
- PRThe Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement PartsIssued on behalf of Conexeu Sciences Inc.A newly listed regenerative-tissue company has put its lead breast-reconstruction matrix on the bench at one of the world's largest bioprinting institutes. For investors tracking the space, the partner it chose may matter more than anything it has said.Equity Insider Market CommentaryTAMPA, Fla., June 2, 2026 /CNW/ -- For more than half a century, the answer to lost tissue has been to manufacture a substitute and put it where the tissue used to be. Replace, don't restore. That logic built the modern implant industry, and it works — up to a point. But it leaves a gap, and the gap shows up in the numbers: roughly two-thirds of the more than 100,000 wome
- PRIntegra LifeSciences to Present at the 2026 Jefferies Global Healthcare ConferencePRINCETON, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that chief financial officer Lea Knight will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026 at 10:30am ET. A live webcast of the presentation will be available on the Integra LifeSciences investor relations website under EVENTS & PRESENTATIONS. About Integra LifeSciencesIntegra LifeSciences (NASDAQ:IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fi
- SECSEC Form SD filed by Integra LifeSciences Holdings CorporationSD - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
- ANALYSTIntegra upgraded by Citigroup with a new price targetCitigroup upgraded Integra from Sell to Neutral and set a new price target of $16.00
- PRRegenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing ItIssued on behalf of Conexeu Sciences Inc.Companies mentioned: Conexeu Sciences Inc. (NASDAQ:CNXU), Integra LifeSciences Holdings Corporation (NASDAQ:IART), Evolus, Inc. (NASDAQ:EOLS), Bioventus Inc. (NASDAQ:BVS), Mesoblast Limited (NASDAQ:MESO)KEY TAKEAWAYSA fresh Nasdaq debut. Conexeu Sciences Inc. (NASDAQ:CNXU) began trading on May 21, 2026, marking the public-market entry of a Reno-based regenerative tissue platform company targeting wound care, breast reconstruction, and aesthetic medicine — three of the largest unmet-need categories in healthcare today.One platform, multiple markets. Conexeu's proprietary CXU™ extracellular matrix platform is designed to scale across multiple addressabl
- INSIDERDirector Hill Barbara B was granted 24,338 shares, increasing direct ownership by 19% to 151,191 units (SEC Form 4)4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
- INSIDERDirector Bradley Keith covered exercise/tax liability with 882 shares, decreasing direct ownership by 0.99% to 88,254 units (SEC Form 4)4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
- INSIDERSEC Form 4 filed by Director Clay Shaundra4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
- INSIDERSEC Form 4 filed by Director Graves Jeffrey A4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
- INSIDERSEC Form 4 filed by Director Lo Renee Wonlai4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
- INSIDERSEC Form 4 filed by Director Schade Christian S4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
- SECSEC Form S-8 filed by Integra LifeSciences Holdings CorporationS-8 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
- SECIntegra LifeSciences Holdings Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
- PRIntegra LifeSciences to Present at the BofA Securities 2026 Health Care ConferencePRINCETON, N.J., May 08, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that chief financial officer Lea Knight will present at the BofA Securities 2026 Health Care Conference on May 12, 2026 at 4:20pm PT. A live webcast of the presentation will be available on the Integra LifeSciences investor relations website under EVENTS & PRESENTATIONS. About Integra LifeSciencesIntegra LifeSciences (NASDAQ:IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fiel
- SECSEC Form 10-Q filed by Integra LifeSciences Holdings Corporation10-Q - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
- SECSEC Form DEFA14A filed by Integra LifeSciences Holdings CorporationDEFA14A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
- SECIntegra LifeSciences Holdings Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
- SECIntegra LifeSciences Holdings Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
- PRIntegra LifeSciences Reports First Quarter 2026 Financial ResultsPRINCETON, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2026. First Quarter 2026 Highlights First quarter revenues of $391.9 million increased 2.4% on a reported basis and 1.3% on an organic basis compared to the prior year. First quarter GAAP earnings per diluted share of $(0.06), compared to $(0.33) in the prior year. Adjusted earnings per diluted share of $0.54, compared to $0.41 in the prior year.Reaffirming 2026 full year revenue guidance of $1.662 billion to $1.702 billion and updating 2026 adjusted earnings
- PRIntegra LifeSciences Announces Leadership TransitionStuart Essig Appointed as Integra's Next President and Chief Executive OfficerMichael McBreen Appointed Chief Commercial Officer PRINCETON, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ:IART), a leading global medical technology company, today announced that Stuart M. Essig, chairman of Integra's Board of Directors (the "Board"), has been appointed president and chief executive officer, effective May 1, 2026. Mr. Essig will continue to serve as chairman. He succeeds Mojdeh Poul who is pursuing other opportunities. The Company also announced that Michael McBreen, currently executive vice president, president, Codman S
- PRIntegra LifeSciences to Host First Quarter 2026 Financial Results Conference Call on May 5, 2026PRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release first quarter 2026 financial results on Tuesday, May 5, 2026, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the con
- SECIntegra LifeSciences Holdings Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
- ANALYSTIntegra downgraded by ArgusArgus downgraded Integra from Buy to Hold
IART FAQ
6 questionsWhat does Integra LifeSciences Holdings Corporation do?
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. It operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, hydrocephalus management systems, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps...Where does IART stock trade?
Integra LifeSciences Holdings Corporation (IART) is listed on NASDAQ.What sector and industry is IART in?
Integra LifeSciences Holdings Corporation operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about IART?
Integra LifeSciences Holdings Corporation has had 8 recent analyst actions on file. The most recent action was from Citigroup: Neutral with a $1600.00 price target on 2026-05-28. Recent price targets range from $1600.00 to $2300.00.What companies are similar to IART?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare IART side-by-side with any of them on Quantisnow.How can I track IART on Quantisnow?
Quantisnow aggregates Integra LifeSciences Holdings Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IART to receive live email and push alerts on every new disclosure.